The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 25 | $1.01 | $25 |
| Jul 9, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 25 | $16.00 | $400 |
| Jul 9, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 25 | — | $0 |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | $1.01 | $3K |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President, Director | Sell(S) | 3K | $16.00 | $40K |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | — | $0 |
| Jul 8, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 1K | $1.01 | $1K |
| Jul 8, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 1K | $16.00 | $16K |
| Jul 8, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 1K | — | $0 |
| Jul 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | $1.01 | $4K |
| Jul 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 6K | $15.67 | $92K |
| Jul 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 3K | $16.24 | $41K |
| Jul 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | — | $0 |
| Jun 30, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 11K | $4.50 | $49K |
| Jun 30, 2026 | Watkins Tim | CMO & Head of Development | Sell(S) | 11K | $16.02 | $174K |
| Jun 30, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 11K | — | $0 |
| Jun 30, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 8K | $1.01 | $8K |
| Jun 30, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | $1.26 | $3K |
| Jun 30, 2026 | Stengone Carmine N. | CEO and President, Director | Sell(S) | 10K | $16.01 | $160K |
| Jun 30, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 8K | — | $0 |
| Jun 30, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | — | $0 |
| Jun 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 29K | $1.01 | $29K |
| Jun 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 29K | $16.04 | $462K |
| Jun 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 29K | — | $0 |
| Jun 26, 2026 | Miralles Gines Diego | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Lyons-Williams Lori | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Ware Olivia C | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Schimmelpennink Evert B. | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Ignelzi Troy A. | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Brady Todd R. | Director | Grant(A) | 19K | — | $0 |
| Jun 26, 2026 | Boyce Sarah | Director | Grant(A) | 19K | — | $0 |
| Jun 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $13.16 | $55K |
| May 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $13.06 | $51K |
| May 1, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 300 | $13.84 | $4K |
| Apr 6, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $13.43 | $56K |
| Mar 2, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | $4.50 | $16K |
| Mar 2, 2026 | Watkins Tim | CMO & Head of Development | Sell(S) | 4K | $15.02 | $54K |
| Mar 2, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | — | $0 |
| Mar 2, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $15.01 | $63K |
| Feb 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $16.01 | $61K |
| Feb 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | $1.01 | $4K |
| Feb 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | — | $0 |
| Feb 25, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | $1.26 | $3K |
| Feb 25, 2026 | Stengone Carmine N. | CEO and President, Director | Sell(S) | 3K | $16.02 | $43K |
| Feb 25, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 3K | — | $0 |
| Feb 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | $1.01 | $4K |
| Feb 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $16.03 | $69K |
| Feb 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 4K | — | $0 |
| Feb 24, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 4K | $1.26 | $6K |
| Feb 24, 2026 | Stengone Carmine N. | CEO and President, Director | Sell(S) | 4K | $16.02 | $70K |
| Feb 24, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 4K | — | $0 |
| Feb 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 100 | $16.00 | $2K |
| Feb 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 100 | $1.01 | $101 |
| Feb 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 100 | — | $0 |
| Feb 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 400 | $1.01 | $404 |
| Feb 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 400 | $16.00 | $6K |
| Feb 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Option exercise(M) | 400 | — | $0 |
| Feb 11, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 400 | $1.26 | $504 |
| Feb 11, 2026 | Stengone Carmine N. | CEO and President, Director | Sell(S) | 400 | $16.00 | $6K |
| Feb 11, 2026 | Stengone Carmine N. | CEO and President, Director | Option exercise(M) | 400 | — | $0 |
| Feb 3, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 3K | $14.82 | $44K |
| Feb 3, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 1K | $15.25 | $18K |
| Jan 30, 2026 | Watkins Tim | CMO & Head of Development | Grant(A) | 160K | — | $0 |
| Jan 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Grant(A) | 160K | — | $0 |
| Jan 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Grant(A) | 7K | — | $0 |
| Jan 30, 2026 | Stengone Carmine N. | CEO and President, Director | Grant(A) | 445K | — | $0 |
| Jan 30, 2026 | Slover Peter T | Chief Financial Officer | Grant(A) | 192K | — | $0 |
| Jan 30, 2026 | Healy John Stephen | General Counsel and Corp Sec | Grant(A) | 206K | — | $0 |
| Jan 28, 2026 | Watkins Tim | CMO & Head of Development | Sell(S) | 3K | $14.09 | $39K |
| Jan 28, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | $4.50 | $16K |
| Jan 28, 2026 | Watkins Tim | CMO & Head of Development | Sell(S) | 811 | $14.48 | $12K |
| Jan 28, 2026 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $10.35 | $38K |
| Jan 5, 2026 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 500 | $11.13 | $6K |
| Dec 29, 2025 | Watkins Tim | CMO & Head of Development | Sell(S) | 4K | $12.06 | $44K |
| Dec 29, 2025 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | $4.50 | $16K |
| Dec 29, 2025 | Watkins Tim | CMO & Head of Development | Option exercise(M) | 4K | — | $0 |
| Dec 23, 2025 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 4K | $12.23 | $51K |
| Jun 26, 2025 | Miralles Gines Diego | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Ware Olivia C | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Lyons-Williams Lori | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Ignelzi Troy A. | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Brady Todd R. | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Schimmelpennink Evert B. | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2025 | Boyce Sarah | Director | Grant(A) | 15K | — | $0 |
| Apr 28, 2025 | Watkins Tim | CMO & Head of Development | Grant(A) | 26K | — | $0 |
| Apr 28, 2025 | Watkins Tim | CMO & Head of Development | Grant(A) | 260K | — | $0 |
| Mar 14, 2025 | Miralles Gines Diego | Director | Grant(A) | 30K | — | $0 |
| Jan 31, 2025 | Stengone Carmine N. | CEO and President, Director | Grant(A) | 300K | — | $0 |
| Jan 31, 2025 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Grant(A) | 110K | — | $0 |
| Jan 31, 2025 | Lorrain Daniel S. | Chief Scientific Officer | Grant(A) | 4K | — | $0 |
| Jan 31, 2025 | Lorrain Daniel S. | Chief Scientific Officer | Grant(A) | 110K | — | $0 |
| Jan 31, 2025 | Slover Peter T | Chief Financial Officer | Grant(A) | 110K | — | $0 |
| Jan 31, 2025 | Healy John Stephen | General Counsel and Corp Sec | Grant(A) | 64K | — | $0 |
| Nov 25, 2024 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 1K | $16.02 | $16K |
| Nov 18, 2024 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 6K | $16.37 | $100K |
| Nov 18, 2024 | Lorrain Daniel S. | Chief Scientific Officer | Sell(S) | 99 | $17.05 | $2K |
| Aug 13, 2024 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Option exercise(M) | 13K | $1.01 | $13K |
| Aug 13, 2024 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Option exercise(M) | 13K | — | $0 |
| Jun 24, 2024 | Boyce Sarah | Director | Grant(A) | 30K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-04-26 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).